Operating Segments (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Summary of segmental information
Total revenues	$ 3,144,620	$ 7,662,822
Loss from Operations	(4,690,668)	(2,960,195)
Amortization and Depreciation Expense	230,630	226,027
Interest Income	6,202	7,444
Stock-Based Compensation	462,170	715,805
Identifiable Assets	4,705,104	8,223,658
Vaccines/BioDefense [Member]
Summary of segmental information
Total revenues	2,919,677	2,010,234
Loss from Operations	(33,636)	(154,395)
Amortization and Depreciation Expense	38,589	42,640
Stock-Based Compensation	44,484	78,622
Identifiable Assets	628,494	689,266
BioTherapeutics [Member]
Summary of segmental information
Total revenues	224,943	5,652,588
Loss from Operations	(2,203,721)	(1,278,156)
Amortization and Depreciation Expense	190,003	181,213
Stock-Based Compensation	84,020	426,666
Identifiable Assets	566,111	753,767
Corporate [Member]
Summary of segmental information
Loss from Operations	(2,453,311)	(1,527,644)
Amortization and Depreciation Expense	2,038	2,174
Interest Income	6,202	7,444
Stock-Based Compensation	333,666	210,517
Identifiable Assets	$ 3,510,499	$ 6,780,625